Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/43065
Title: | Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy | Authors: | Henríquez-Hernández, Luis Alberto Murias-Rosales, Adolfo González-Hernández, Ana de León, Antonio Cabrera Díaz-Chico, Nicolás Fernández-Pérez, Leandro |
Keywords: | Acute Lymphoblastic-Leukemia Methylenetetrahydrofolate Reductase C677T Colorectal-Cancer Thymidylate Synthase Clinical-Practice, et al |
Issue Date: | 2010 | Publisher: | 1877-7821 | Journal: | Cancer Epidemiology | Abstract: | Purpose To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Results Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p = 0.018) and 7.0 (95% confidence interval, 1.2-40.5; p = 0.029), respectively). Conclusion We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer. (C) 2010 Elsevier Ltd. All rights reserved. | URI: | http://hdl.handle.net/10553/43065 | ISSN: | 1877-7821 | DOI: | 10.1016/j.canep.2010.06.013 | Source: | Cancer Epidemiology[ISSN 1877-7821],v. 34, p. 634-638 |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
29
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
27
checked on Mar 30, 2025
Page view(s)
104
checked on Jan 11, 2025
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.